Summary
Irina Degtiar is a Principal Therapeutic Area & Methodology Statistician with a Ph.D. in Biostatistics from Harvard and over a decade of experience turning observational healthcare data into policy- and product-changing evidence. She has led high-stakes analyses used by CMS, medical device companies, and health technology assessment bodies, blending causal inference, generalizability/transportability methods, Bayesian modeling, and machine learning across claims, EHR, lab, survey, and trial data. Her award-winning research bridges statistics and economics, and she routinely translates technical findings for clinicians, payers, and policy makers while remaining hands-on in R and Stan. Known for pragmatic study and economic model design, she has a track record of advising scaling decisions for nationwide policy pilots and informing trial go/no-go choices. Based in Cambridge, MA, she combines academic rigor with applied impact, often developing novel methods that directly shape reimbursement and access decisions.
8 years of coding experience
11 years of employment as a software developer
BA BS Molecular and Cellular Biology; Business Administration, BA BS Molecular and Cellular Biology; Business Administration at University of California, Berkeley
Master's Degree (M.S.) Biostatistics, Master's Degree (M.S.) Biostatistics at University of Michigan
Business Administration Molecular Biology, Business Administration Molecular Biology at Freie Universität Berlin
Doctor of Philosophy (Ph.D.) Biostatistics, Doctor of Philosophy (Ph.D.) Biostatistics at Harvard T.H. Chan School of Public Health
German, Russian, Spanish, English, French